Insulin Pen With Half-Unit Dosing Now Available in U.S. For Children and Young Adults

NovoPen(R) Junior Is Designed For Easy, Accurate and Flexible Insulin Administration

PRINCETON, N.J., Jan. 7 /PRNewswire-FirstCall/ — Novo Nordisk today

announced the availability of NovoPen(R) Junior, an insulin delivery system

for children and adults that features half-unit dosing increments, which

allows insulin doses to be finely tuned for patient needs. Designed to make

insulin administration easy, accurate and flexible, NovoPen Junior is a line

extension of the company’s NovoPen(R), the most widely used insulin pen in the

world.

“NovoPen Junior fills an important need among children and young adults

because it allows half-unit dosing,” said Harold Starkman, MD, at the

Pediatric Diabetes Center, Morristown Memorial Hospital, Morristown, NJ. He

explained that, because of their small body size, many children with diabetes

require only small amounts of insulin to maintain proper control — with some

requiring very finely tuned doses. “NovoPen Junior allows people with

diabetes, particularly children and young adults, to administer insulin more

accurately to meet their needs,” he said.

Dr. Starkman said that the incidence of diabetes is increasing

dramatically in children. “It’s more important than ever before to make

insulin therapy as easy and as accurate as possible for those who need it,” he

said. He added that the bright and colorful look of NovoPen Junior may

encourage children to more easily accept and incorporate a daily insulin

regimen into their lives.

NovoPen Junior is available in two fun colors, to help patients tell their

different insulin types apart. Insulin therapy is administered with NovoPen

Junior by dialing the dose, inserting the needle, and pushing the injection

button. The dosage dial is graduated in half-unit markings and can administer

from one to 35 units.

NovoPen Junior is designed for use with Novo Nordisk’s range of PenFill(R)

3 mL cartridges, which contain 300 units of insulin. It is used with

NovoFine(R) disposable needles, including NovoFine 31-gauge (6 mm) needles,

whose design may help make insulin injections more comfortable.

NovoPen Junior is available as part of a complete diabetes management

system. The NovoPen(R) Junior Diabetes Management System includes: NovoPen

Junior, an interactive CD-ROM of games and activities that explain diabetes

and its treatment, an instructional video and brochure, a parent Q&A booklet,

NovoFine 31 disposable needles, and NovoPen(R)3 PenMate(R), an automatic

needle insertion device which hides the needle and is designed for quick, easy

injections. Shown to significantly reduce pain perception(1), NovoPen 3

PenMate was considered easy to use by 84% (N=57) of patients in a study(1).

About diabetes

The prevalence of diabetes is skyrocketing in many countries around the

world. In the United States, 17 million people, or 6.2 % of the population,

have diabetes, with an estimated 5.9 million sufferers unaware they have the

disease. Approximately 2,740 people are diagnosed with diabetes daily, and

nearly 1 million people will be diagnosed this year. Diabetes is the fifth

leading cause of death by disease in the United States.(2)

Among North American children and adolescents, the prevalence of type 2

diabetes has been rising at a dramatic rate. Prevalence has been estimated at

between 2 and 50 per 1000 in various populations, which represents as much as

a ten-fold increase over the past two decades.(3)

NovoPen, PenMate, PenFill, and NovoFine are registered trademarks of Novo

Nordisk A/S and are protected by U.S. patents and patents pending.

Always read the Instruction Manual for complete directions for use.

Novo Nordisk is a focused healthcare company and the world leader in

diabetes care. In addition, Novo Nordisk has a leading position within areas

such as hemostasis management, growth hormone therapy and hormone replacement

therapy. Novo Nordisk manufactures and markets pharmaceutical products and

services that make a significant difference to patients, the medical

profession and society.

With headquarters in Denmark, Novo Nordisk employs approximately 17,900

people in 68 countries and markets its products in 179 countries. For further

company information visit http://www.novonordisk.com.

References

(1) Diglas J, et al. Reduced pain perception with PenMate(R), an automatic

needle insertion device for use with an insulin pen. Data on file, Novo

Nordisk Pharmaceuticals, Inc.

(2) American Diabetes Association website, http://www.diabetes.org. Basic

Diabetes Information: Facts & Figures and National Diabetes Fact Sheet.

(3) Ludwig D and Ebbeling C. Type 2 diabetes mellitus in children:

Primary care and public health considerations. JAMA 2001; 1427-1430.

1 Star2 Stars3 Stars4 Stars5 Stars (91 votes, average: 3.05 out of 5)
Loading...



Leave a Reply